This international prize, established in 2002, encourages the work of promising young neurobiologists by providing support in the early stages of their careers. It is awarded annually for the most outstanding neurobiological research by a young scientist, as described in a 1,000-word essay based on research performed during the past three years.
The winner will receive US$25,000 and publication of his or her essay in Science. The essays of up to three finalists will also be published on Science Online.
Researchers who are 35 or younger are invited to apply by 15 June. The prizewinner will be selected by a committee of independent experts in the field, chaired by Science’s senior editor, Peter Stern.
The 2010 prize was won by Christopher Gregg, Postdoctoral Fellow at Harvard University for his research on maternal and paternal gene expression in the brain.
2011 Neurobiology Prize open for entries
Organised by Eppendorf and Science journal
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines